18,250 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Triglav Skladi D.O.O.

Triglav Skladi D.O.O. purchased a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 18,250 shares of the medical research company's stock, valued at approximately $1,025,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EXAS. Assenagon Asset Management S.A. raised its position in shares of Exact Sciences by 130.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 22,801 shares of the medical research company's stock worth $1,281,000 after buying an additional 12,912 shares in the last quarter. Avanza Fonder AB bought a new stake in shares of Exact Sciences during the 4th quarter worth about $1,096,000. Merit Financial Group LLC bought a new stake in shares of Exact Sciences during the 4th quarter worth about $235,000. Artemis Investment Management LLP raised its position in shares of Exact Sciences by 139.6% during the 4th quarter. Artemis Investment Management LLP now owns 255,842 shares of the medical research company's stock worth $14,376,000 after buying an additional 149,067 shares in the last quarter. Finally, Eagle Wealth Strategies LLC raised its position in shares of Exact Sciences by 25.0% during the 4th quarter. Eagle Wealth Strategies LLC now owns 5,000 shares of the medical research company's stock worth $281,000 after buying an additional 1,000 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Stock Down 0.7%

Shares of EXAS stock traded down $0.41 during trading on Thursday, hitting $56.48. 2,680,348 shares of the company were exchanged, compared to its average volume of 2,589,879. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The firm has a market capitalization of $10.65 billion, a price-to-earnings ratio of -10.14 and a beta of 0.92. The business's 50-day simple moving average is $47.12 and its 200 day simple moving average is $52.06. Exact Sciences Co. has a twelve month low of $39.97 and a twelve month high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.16. The firm had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company's revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.60) earnings per share. As a group, analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on EXAS shares. Guggenheim reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Exact Sciences in a research note on Friday, April 11th. Barclays lifted their price objective on shares of Exact Sciences from $55.00 to $75.00 and gave the stock an "overweight" rating in a research note on Friday, May 2nd. Piper Sandler lowered their price objective on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Mizuho assumed coverage on shares of Exact Sciences in a research note on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price objective on the stock. Finally, Evercore ISI lifted their target price on shares of Exact Sciences from $60.00 to $66.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $70.90.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.